SUMMIT, N.J.--(BUSINESS WIRE)--Celgene Corporation (NASDAQ: CELG):
2011 First Quarter Financial Results Year-Over-Year
* Non-GAAP Total Revenue Increased 40 Percent to $1.11 Billion; GAAP Total Revenue $1.13 Billion * Global REVLIMID Net Product Sales Increased 39 Percent to $738 Million * Global VIDAZA® Net Product Sales Increased 36 Percent to $163 Million * Global THALOMID® Net Product Sales of $85 Million * Global ABRAXANE® Net Product Sales of $74 Million * Non-GAAP Operating Income Increased 35 Percent to $486 Million; GAAP Operating Income $288 Million * Non-GAAP Net Income Increased 34 Percent to $393 Million; GAAP Net Income $256 Million * Non-GAAP Diluted Earnings Per Share Increased 32 Percent to $0.83; GAAP Diluted Earnings Per Share $0.54
